Improving the safety profile of warfarin

Seminars in Hematology

Volumn 39, Issue 3, 2002, Pages 179-186

  Chai, S Jean ^a   Macik, B Gail ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; DOSE RESPONSE; DRUG SAFETY; GENETIC DIFFERENCE; HUMAN; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; TREATMENT PLANNING; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; INTERNATIONAL NORMALIZED RATIO; STANDARD;

ANTICOAGULANTS; DRUG MONITORING; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; WARFARIN;

EID: 0035992707     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.34089     Document Type: Article

References (55)

1. Managing oral anticoagulant therapy
2. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management
3. Association of polymorphisms in the cytochrome P 450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
4. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy
5. Management of warfarin (coumarin) overdose
6. Acute cardiovascular collapse after intravenous phytonadione
7. Experience with patient self-management of oral anticoagulation
8. Recombinant FVIIa in the treatment of warfarin bleeding
9. Course, management and outcome of oral-anticoagulant-related intracranial haemorrhages
10. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
11. Use of factor 1X complex in warfarin-related intracranial hemorrhage
12. A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurements
13. Management of oral anticoagulant-induced intracranial haemorrhage
14. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses
15. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies
16. Management of intracranial bleeding associated with anticoagulation: Balancing the risk of further bleeding against thromboembolism from prosthetic heart valves
17. A review of enzyme induction of warfarin metabolism with recommendations for patient management
18. A randomized trial comparing 5-mg and 10-mg warfarin loading doses
19. Treatment of warfarin-associated coagulopathy with oral vitamin K: A randomised controlled trial
20. Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratios (INR) and prothrombin times (PT) induced by warfarin
21. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0
22. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Laboratory monitoring of oral anticoagulant therapy
23. The risk for and severity of bleeding complications in elderly patients treated with warfarin
24. Performance of the Coumatrack system in a large anticoagulation clinic
25. Emergency reversal of anticoagulation after intracerebral hemorrhage
26. Comparison of 5-mg and 10-mg loading doses in intiation of warfarin therapy
27. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses
28. Self-management of oral anticoagulant therapy after heart valve replacement
29. Tolerability of a new vitamin K1 preparation for parenteral administration to adults: One case of anaphylactoid administration
30. NovoSeven as a universal haemostatic agent
31. Prothrombin complex concentrates: Indications, contraindications, and risks: A task force summary
32. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
33. Optimal frequency of patient monitoring and intensity of anticoagulation therapy in valvular heart disease
34. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization
35. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin
36. Patient self-management of oral anticoagulation therapy: An international update
37. Anticoagulant-related intracerebral hemorrhage
38. Anticoagulant-related bleeding: Clinical epidemiology, prediction and prevention
39. Hemorrhagic complications of anticoagulation treatment
40. Management of warfarin-induced bleeding
41. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy
42. Genetic control of anticoagulation
43. Genetic modulation of oral anticoagulation with warfarin
44. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting
45. The use of recombinant activated factor VII in congenital and acquired factor VII deficiencies
46. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors
47. Bleeding complications of oral anticoagulant treatment: An inception cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy
48. The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation
49. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on blood component therapy
50. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione
51. Reversal of warfarin using recombinant factor VIIa prior to invasive procedures
52. Genetic association between sensitivity to warfarin and expression of CYP2C9* 3
53. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation
54. Correction of excessive anticoagulation with low-dose oral vitamin K1
55. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation